
BridgeBio Pharma Inc
NASDAQ:BBIO

Intrinsic Value
The intrinsic value of one
BBIO
stock under the Base Case scenario is
45.88
USD.
Compared to the current market price of 43.99 USD,
BridgeBio Pharma Inc
is
Undervalued by 4%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
BridgeBio Pharma Inc
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
BridgeBio Pharma Inc
Balance Sheet Decomposition
BridgeBio Pharma Inc
Current Assets | 695.2m |
Cash & Short-Term Investments | 540.6m |
Receivables | 115.3m |
Other Current Assets | 39.3m |
Non-Current Assets | 186.5m |
Long-Term Investments | 128.2m |
PP&E | 13.9m |
Intangibles | 27.8m |
Other Non-Current Assets | 16.6m |
Free Cash Flow Analysis
BridgeBio Pharma Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
BridgeBio Pharma Inc
Revenue
|
127.4m
USD
|
Cost of Revenue
|
-5.9m
USD
|
Gross Profit
|
121.5m
USD
|
Operating Expenses
|
-806.4m
USD
|
Operating Income
|
-684.9m
USD
|
Other Expenses
|
16.9m
USD
|
Net Income
|
-668m
USD
|
BBIO Profitability Score
Profitability Due Diligence
BridgeBio Pharma Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Score
BridgeBio Pharma Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
BBIO Solvency Score
Solvency Due Diligence
BridgeBio Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Score
BridgeBio Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BBIO Price Targets Summary
BridgeBio Pharma Inc
According to Wall Street analysts, the average 1-year price target for
BBIO
is 61.38 USD
with a low forecast of 42.42 USD and a high forecast of 99.75 USD.
Dividends
Current shareholder yield for BBIO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BBIO
stock under the Base Case scenario is
45.88
USD.
Compared to the current market price of 43.99 USD,
BridgeBio Pharma Inc
is
Undervalued by 4%.